Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection
- 36 Downloads
We read with interest the work by Tobudic et al.  on the on- and off-label use of long-acting lipoglycopeptide (laLGP) dalbavancin, which highlights the effectiveness and safety of this new antibiotic used in a cohort of 46 patients with both skin and soft tissue infections and commonly encountered deep-seated, often severe, infections. These results certainly look very promising and could lead to an expansion of the use limits of dalbavancin; both the approved laLGPs, i.e., oritavancin and dalbavancin, are currently approved only for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive germs. However, some clinical-practice experiences [2, 3] and a recent clinical trial  demonstrated the efficacy of dalbavancin also for the treatment of deep-seated infections that usually require prolonged intravenous antibiotic therapy, thus resulting not only in an advantage in tolerability but also in...
This study was performed as part of our routine work.
Compliance with ethical standards
Conflict of interest
All authors have no conflict of interest to report.
- 5.Knafl D, Tobudic S, Cheng SC, et al. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36:677–80. https://doi.org/10.1007/s10096-016-2845-z.CrossRefPubMedGoogle Scholar